A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
about
Targeted prodrug design to optimize drug delivery.The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental dataAnti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in miceTranslating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase.Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs.Targeting enzymes for cancer therapy: old enzymes in new roles.Identification of a novel Baeyer-Villiger monooxygenase from Acinetobacter radioresistens: close relationship to the Mycobacterium tuberculosis prodrug activator EtaA.Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy.The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.Diamagnetic Imaging Agents with a Modular Chemical Design for Quantitative Detection of β-Galactosidase and β-Glucuronidase Activities with CatalyCEST MRI.Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.
P2860
Q34461985-E22512CF-4963-4A9E-91F7-E3F9E2CC19A3Q36115888-872B759D-DD36-4A64-BFC2-27C4F826CE75Q36795109-20CF0DBF-A69A-44C4-A91B-1C8E1C0042EBQ37352745-6AFA39EF-A59D-40D6-8CD3-A700DEE43C16Q38979784-D3C2D6E4-EA48-4DCF-996D-66A42E5E056DQ40181563-C8B0FA89-2E7F-4EE1-93C5-B73B32C67A2FQ40230260-CD2ABD2C-F097-4314-AC7D-65032422169EQ40820608-BC7B52E7-E7ED-4DB1-A9D6-5571AA5F7568Q41507993-CE60E40E-2155-4E62-A23F-39F48773F892Q42590388-9618E131-4516-4B78-B404-C5CB584CE795Q42923930-ECE9FA6A-4401-4E58-9FAE-38B31B13F585Q45866504-8941DBD6-370C-434A-BED1-D41BD4D9D0DAQ45878398-9EF5A574-9C80-4CE4-834F-4AE0C0CDCC49Q47978690-D5AB6506-FB16-499F-BD7B-CCEA5C143A78Q51156646-06C5A489-C5DD-4A86-B8C6-2BCC15A98A0BQ54646041-5059FCBD-2B97-4B05-B201-510A84DA635C
P2860
A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
A monoclonal antibody-beta-glu ...... specific treatment of cancer.
@ast
A monoclonal antibody-beta-glu ...... specific treatment of cancer.
@en
type
label
A monoclonal antibody-beta-glu ...... specific treatment of cancer.
@ast
A monoclonal antibody-beta-glu ...... specific treatment of cancer.
@en
prefLabel
A monoclonal antibody-beta-glu ...... specific treatment of cancer.
@ast
A monoclonal antibody-beta-glu ...... specific treatment of cancer.
@en
P2093
P2860
P356
P1476
A monoclonal antibody-beta-glu ...... r specific treatment of cancer
@en
P2093
H M Pinedo
M van Muijen
W J van der Vijgh
P2860
P2888
P304
P356
10.1038/BJC.1992.298
P407
P577
1992-09-01T00:00:00Z